⌘K
t
| Date | 21 Feb 2022 |
| Time | 10:00:04 |
| Category | Miscellaneous |
| ID | 2768C |
21 February 2022
Physiomics plc
("Physiomics" or "the Company")
DoseMeRx Update
Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, would like to provide an update on its collaboration with Tabula Rasa Healthcare Inc ("TRHC") in the field of oncology (first announced in December 2020) following THRC's recent press release regarding the intended sale of its DoseMeRx solution.
Physiomics' personalised dosing application for docetaxel in prostate cancer was successfully integrated into the DoseMeRx platform over the course of 2021. Following positive feedback on this proof of concept implementation, Physiomics and DoseMeRx are exploring further development in other cancer indications that may offer more significant commercial potential. During the sale process announced by TRHC, Physiomics continues to work with DoseMeRx and looks forward to further developing the collaboration with DoseMeRx's new owners as and when the transaction is completed.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0)20 3764 2341
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 90 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.
For more information please visit: